Beclomethasone Nasal

Introduction Overview

Generic Name

beclomethasone nasal

Brand Name

QNASL

Dosage Form

Nasal Aerosol Spray

Drug Class

Nasal steroids

Pharmacokinetics

Absorption:
Beclomethasone administered via the nasal route is designed to exert local effects within the nasal mucosa. After intranasal administration, a portion of the dose deposits on the nasal mucosa where it is absorbed. Systemic absorption of intranasal beclomethasone is minimal due to its low bioavailability, primarily because substantial first-pass metabolism occurs if swallowed portions reach the gastrointestinal tract. This minimized systemic absorption contributes to a lower risk of systemic corticosteroid effects. The onset of clinical efficacy generally requires several days, with maximal therapeutic effects observed after approximately two weeks of regular use.

Distribution:
Following absorption, beclomethasone exhibits a large volume of distribution indicating extensive tissue binding. It is highly lipophilic and distributes into the nasal mucosal tissues where it exerts its anti-inflammatory action. Plasma protein binding is extensive, which aids in the localization of the drug effects and limits free circulating corticosteroid. The drug's distribution profile supports reduced systemic exposure and targeted nasal action.

Metabolism:
Beclomethasone is extensively metabolized in the liver via cytochrome P450 3A4 enzymes to active and inactive metabolites. The primary metabolite, beclomethasone-17-monopropionate (17-BMP), retains glucocorticoid activity but systemic levels remain low due to minimal absorption and rapid metabolism. This high first-pass metabolism substantially reduces systemic corticosteroid exposure after intranasal use, decreasing the likelihood of systemic side effects common to corticosteroids.

Elimination:
The elimination of beclomethasone and its metabolites occurs mainly via renal excretion of conjugated metabolites, with a minor portion eliminated in feces. The elimination half-life of beclomethasone and its active metabolites ranges between approximately 2 to 4 hours, supporting once or twice daily dosing regimens. Efficient clearance minimizes accumulation during chronic use.

Clinical Implications:
The pharmacokinetic profile of QNASL supports its clinical use as a targeted therapy for nasal allergy symptoms, providing effective localized anti-inflammatory action while minimizing systemic corticosteroid exposure and side effects. Its slow onset necessitates patient adherence to prescribed dosing schedules. The minimal systemic absorption has been demonstrated to limit effects on the hypothalamic-pituitary-adrenal axis, important for safety in both adults and pediatric populations.

Dosage Forms

Available Dosage Forms:
QNASL is formulated as a nasal aerosol spray available in the following dosages:
- 40 mcg per spray (intended primarily for pediatric patients aged 4 to 11 years)
- 80 mcg per spray (used in adults and adolescents 12 years and older)
The nasal spray device contains a metered-dose mechanism providing a precise amount of medication per actuation, with a total of 120 sprays per bottle. This unit-dose design facilitates accurate dosing and patient compliance.

Dosages for Adults and Adolescents:
- For patients aged 12 years and older, the usual dose is 1 to 2 sprays into each nostril once per day. The exact dosing may be adjusted by the physician based on clinical response but should not exceed 4 sprays total per day.

Dosages for Specific Patient Populations:
- Pediatric patients aged 4 to 11 years are recommended to use the 40 mcg/spray formulation, typically administered as 1 spray in each nostril once daily.
- QNASL is not recommended for children under 4 years of age.
- Dosage adjustments or careful monitoring may be necessary in patients with pre-existing nasal mucosal injury, nasal surgery, or severe nasal infections.

Clinical Guidelines:
The nasal spray should be used consistently daily to achieve optimal control of nasal allergy symptoms. Initial onset of benefit may take several days, up to two weeks. The bottle should be discarded after 120 sprays have been used or if the dose indicator shows zero to ensure accurate dosing. Patients should follow instructions on priming the spray before initial use and properly dispose of the product after completion.

Mechanism Of Action

Beclomethasone nasal, the active ingredient in QNASL, is a synthetic corticosteroid with potent local anti-inflammatory properties. Its primary molecular mechanism involves binding to glucocorticoid receptors within nasal mucosal cells, thereby modulating gene expression and inhibiting the production and release of inflammatory mediators such as prostaglandins, leukotrienes, and cytokines. This results in a decrease in nasal mucosal inflammation, edema, and hyper-reactivity.

At the cellular level, beclomethasone reduces infiltration and activation of inflammatory cells including eosinophils, mast cells, and lymphocytes into the nasal mucosa. It stabilizes cellular membranes preventing release of histamine and other mediators that contribute to allergy symptoms. Additionally, it inhibits vascular permeability and capillary dilation, thus reducing nasal congestion and rhinorrhea.

Biochemically, beclomethasone induces the synthesis of anti-inflammatory proteins such as lipocortin-1, which suppresses phospholipase A2 activity, a key enzyme in the arachidonic acid pathway. This blockade results in decreased synthesis of pro-inflammatory prostaglandins and leukotrienes. These pathways culminate in alleviation of allergic rhinitis symptoms including sneezing, nasal itchiness, and runny nose.

Clinically, the therapeutic implications of this mechanism are evident in QNASL's efficacy in treating both seasonal and perennial allergic rhinitis in adults and children aged 4 years and older. Compared with other nasal corticosteroids, QNASL offers targeted delivery with low systemic bioavailability, reducing systemic corticosteroid-related side effects. Clinical trials have demonstrated significant symptom relief with regular use, supporting its role as a first-line nasal steroid therapy. Research continues to explore its optimal dosing strategies and comparative effectiveness versus other intranasal corticosteroids.

Pharmacological Actions

Potent local anti-inflammatory activity in nasal mucosa
Suppression of release of inflammatory mediators such as prostaglandins and leukotrienes
Reduction of nasal mucosal edema and hyperemia
Inhibition of infiltration and activation of eosinophils, mast cells, and lymphocytes
Stabilization of cellular membranes to prevent mediator release
Decreased vascular permeability reducing nasal congestion
Induction of anti-inflammatory proteins like lipocortin-1
Minimal systemic absorption leading to reduced systemic side effects
Long duration of action allowing once or twice daily dosing
Improvement of nasal airway patency and reduction of allergic symptoms
Immunomodulatory actions that limit hypersensitivity responses
Reduction of sneezing, nasal itchiness, and rhinorrhea symptoms
Suppression of allergic rhinitis pathophysiological pathways

Therapeutic Or Clinical Uses

Treatment of seasonal allergic rhinitis symptoms (e.g., sneezing, nasal congestion, runny nose) in adults and children 12 years and older
Management of perennial (year-round) allergic rhinitis in adults and adolescents
Relief of nasal allergy symptoms such as nasal congestion, sneezing, runny nose, and nasal itching
Treatment of nasal symptoms associated with allergic rhinitis in pediatric patients aged 4 to 11 years (40 mcg formulation)
Reduction of nasal mucosal inflammation caused by allergens
Prevention of recurrence of nasal allergy symptoms with continued use
Alternate therapy for patients who are unresponsive or intolerant to oral antihistamines
Adjunct therapy to systemic corticosteroids in severe allergic rhinitis
Used preoperatively to reduce nasal mucosal swelling before nasal surgery (off-label)
Management of nasal congestion related to non-infectious nasal inflammation
Symptom control in patients with concomitant asthma and allergic rhinitis
Improvement of quality of life in patients with allergic rhinitis by reducing bothersome nasal symptoms
Potential off-label use in certain inflammatory nasal conditions as determined by clinicians

Side Or Adverse Effects

Nasal discomfort or irritation including burning or stinging sensation
Sneezing following nasal spray administration
Runny nose (rhinorrhea) or nasal stuffiness
Nosebleeds (epistaxis), occasionally severe or persistent
Development of nasal sores or ulcers that do not heal
Headache and occasional nausea reported in some patients
Unpleasant taste or smell following nasal spray use
Fever or sore throat potentially related to secondary infection
Blurred vision, eye pain, or halos around lights indicating possible ocular side effects
Signs of infection such as chills, sores or white patches in or around the nose
Potential systemic corticosteroid side effects with prolonged high-dose use including thinning skin and easy bruising
Suppression of growth rates in pediatric patients with chronic use
Rare allergic reactions including hives, facial swelling, or difficulty breathing
Hormonal disturbances presenting as fatigue, muscle weakness, nausea, vomiting, weight changes
Increased susceptibility to infections due to local immune suppression

Precautions

Inform healthcare provider of any recent infections or illnesses before initiating therapy
Use cautiously in patients with glaucoma, cataracts, or herpes simplex infection of the eyes
Avoid use in individuals with active tuberculosis or untreated nasal ulcers and sores
Monitor nasal mucosa regularly during prolonged therapy for signs of mucosal injury
Avoid exposure to chickenpox or measles during treatment due to immunosuppressive effects
Use cautiously in pediatric patients due to potential corticosteroid effects on growth
Do not exceed recommended dose to minimize risk of systemic corticosteroid effects
Avoid getting medication into eyes; rinse thoroughly with water if accidental exposure occurs
Patients should follow prescribed dosing schedule and attend scheduled medical follow-ups
Contact a healthcare provider if symptoms do not improve within 1 to 2 weeks of therapy
Use cautiously in patients with a history of nasal surgery or trauma
Pregnancy and breastfeeding patients should consult a healthcare provider before use
Patients with known hypersensitivity to beclomethasone or other corticosteroids should avoid use
Avoid sharing the nasal spray device to reduce risk of cross-infection
Consider risk-benefit assessment in immunocompromised patients

Warnings

Not for use in children under 4 years of age
May take up to two weeks of regular use before symptom improvement is observed
Potential for nasal mucosal damage or ulceration; seek medical advice if persistent nosebleeds or sores develop
Long-term use may suppress the hypothalamic-pituitary-adrenal axis especially at high doses
Risk of ocular side effects such as glaucoma and cataracts; patients with pre-existing eye conditions should be monitored
Avoid contact with eyes; rinse with water immediately if accidental exposure occurs
Avoid close contact with individuals who have contagious infections like chickenpox or measles
Beclomethasone may reduce the body's ability to fight infections; monitor for signs of systemic or local infections
Missed doses should not be doubled; continue with the regular dosing schedule
Overdose is unlikely to cause acute life-threatening symptoms but chronic overuse can have corticosteroid-related adverse effects
Notify healthcare provider if unusual fatigue, muscle weakness, or hormonal symptoms develop
Monitor growth in pediatric patients; report any slowed or halted growth to the physician
Medical supervision is necessary during long-term therapy to assess efficacy and safety
Discontinue and seek emergency care if signs of allergic reaction such as swelling or breathing difficulties occur
Patients should not share medication devices to avoid cross-contamination

Contraindication

Known hypersensitivity or allergy to beclomethasone or any formulation components
Active untreated nasal infections including tuberculosis or herpes simplex infection of the nasal mucosa
Presence of nasal sores, ulcers, or trauma contraindicating nasal steroid administration
Children under 4 years of age due to insufficient safety and efficacy data
Patients with systemic fungal infections or immunosuppression not under close medical supervision
Use in individuals with recent nasal surgery or injury without medical clearance
Known hypersensitivity to corticosteroids or preservatives used in the nasal spray formulation
Concomitant use with other intranasal corticosteroids without medical direction
Patients with severe ocular infections related to steroid use
Severe uncontrolled infections where immunosuppression may worsen outcomes
Patients with known hypersensitivity to any additives or propellants used in the nasal aerosol spray
Any contraindications listed for systemic corticosteroid therapy apply with caution
Avoid use if actively experiencing an acute infection unless medically advised
Contraindicated in patients with hypersensitivity reactions to similar topical corticosteroids
Patients exhibiting symptoms of severe allergic reaction after use

Drug Interactions

Concurrent use with other corticosteroid-containing products may increase systemic corticosteroid exposure
Drugs that inhibit or induce cytochrome P450 3A4 enzymes may alter beclomethasone metabolism and affect systemic exposure
Co-administration with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) could increase the risk of systemic corticosteroid side effects
Use with caution if patient is receiving immunosuppressant therapy to avoid compounded immunosuppression
Combination with other nasal decongestants may increase risk of nasal irritation or mucosal damage
Concurrent use with anticoagulants should be monitored closely due to potential increased bleeding risk
Interactions with antihistamines are not common but may impact overall allergy control strategies
Use with vaccines, especially live vaccines, may require special consideration due to potential immunosuppression
Concomitant use with systemic corticosteroids may potentiate systemic adverse effects
Potential additive effects with medications causing nasal mucosal dryness or irritation
Interaction with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy of beclomethasone
Careful monitoring required when used with drugs affecting the hypothalamic-pituitary-adrenal axis
Herbal supplements with immunomodulatory properties may interact and alter therapy effectiveness
Alcohol ingestion does not have a known direct interaction but may exacerbate side effects
Patients should inform their healthcare providers of all prescription, over-the-counter, and herbal products they are using

Preparations Of The Drug

QNASL Nasal Aerosol Spray 40 mcg per spray, intended for children aged 4-11 years
QNASL Nasal Aerosol Spray 80 mcg per spray, intended for adults and adolescents aged 12 years and older
A metered-dose nasal aerosol spray device containing 120 metered sprays per bottle
Formulated as a suspension aerosol for nasal administration
Preserved and formulated to maintain stability and efficacy of the corticosteroid powder
Supplied with patient instructions detailing priming, administration, and disposal procedures
Stored at room temperature, upright, protected from moisture and heat to preserve integrity
Single bottle intended for single patient use with a built-in dose indicator to track remaining doses
Packaging designed to minimize contamination and allow consistent dosing throughout usage
Available only by prescription due to steroid classification and monitoring requirements
Manufactured under sterile conditions to reduce risk of nasal infections
Not formulated for oral or systemic administration, specifically designed for intranasal delivery
Comes with packaging that includes a patient information leaflet detailing side effects and precautions
Supplied in compliance with regulatory standards governing nasal corticosteroid products
Formulation ensures rapid deposition on nasal mucosa for localized drug delivery and action